Drugs / AR-67
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00389480 | Oct 2006 → Feb 2009 | neoplasm | Arno Therapeutics | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01124539 | Dec 2009 → Sep 2014 | gliosarcoma | Arno Therapeutics | Unknown | No outcome recorded |
| Phase 2 | NCT00956787 | Jun 2009 → Jul 2014 | myelodysplastic syndrome | Arno Therapeutics | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AR-67 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00389480 ↗ |
| Known as | DB-67 | “AR-67 (formerly DB-67) represents a rationally engineered drug” NCT00389480 ↗ |
| Known as | NSC-708298 | ChEMBL registry synonym — accepted as the source's own label CHEMBL412309 ↗ |
| Known as | Silatecan | ChEMBL registry synonym — accepted as the source's own label CHEMBL412309 ↗ |
| Action | Inhibit | “DNA topoisomerase I inhibitor” CHEMBL412309 ↗ |
| Modality | Small molecule | — CHEMBL412309 ↗ |
| Route | Intravenous | “intravenous AR-67 (formerly DB-67) administered once daily for 5 days every 21 days” NCT00389480 ↗ |
| Target | TOP1 | “DNA topoisomerase I inhibitor” CHEMBL412309 ↗ |